Phase 3 study · Novartis · NCT07326709
Novartis's phase 3 votoplam study for Huntington disease
About 770 adults with early symptomatic Huntington disease are planned, and 3 of every 5 get votoplam by mouth and the rest a placebo. Neither participants nor the study team know which, and each person's treatment lasts up to 36 months.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when Novartis's phase 3 votoplam study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your neurologist.
1. Are you between 21 and 70 years old, and still able to walk?
2. Has a genetic test confirmed your Huntington disease, with a CAG repeat length of 40 or more?
The listing asks for the genetic result and the CAG repeat number to be known before screening. Your neurologist or genetics clinic can tell you your CAG repeat number.3. Have you ever had a gene therapy, a cell transplant or any other experimental brain surgery for Huntington disease?
4. Do you have active hepatitis B or hepatitis C, HIV or another immune deficiency disease?
The listing defines active hepatitis B and C by specific blood test results. Your neurologist can help you find your latest hepatitis and HIV test results.5. Have you been diagnosed with a serious heart rhythm problem, such as sustained ventricular tachycardia or heart block without a pacemaker?
6. Has anyone in your family been diagnosed with long QT syndrome or a heart rhythm called torsade de pointes?
The study team also checks for these, which are easier to go over with your neurologist:
- Huntington disease rating scale scores, an Independence Scale of 90 or more, Total Functional Capacity of 13 and Total Motor Score of 7 to 25
- A CAP100 score of 70 or more, worked out from age at study entry and CAG repeat length
- Highly effective birth control for women who could become pregnant, while taking the study drug and for 8 months after
- Pregnancy or breastfeeding
- Other criteria in the full study protocol, which the public listing does not spell out
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- University of Alabama BirminghamBirmingham, Alabama · Recruiting
- Univ of Arkansas for Med SciencesLittle Rock, Arkansas · Recruiting
- University of CA San DiegoLa Jolla, California · Recruiting
- UC Davis Health SystemSacramento, California · Recruiting
- UCSFSan Francisco, California · Recruiting
- Stanford HealthcareStanford, California · Recruiting
- CenExcel Rocky Mtn Clin ResearchEnglewood, Colorado · Recruiting
- U Conn HealthFarmington, Connecticut · Recruiting
- Georgetown UniversityWashington D.C., District of Columbia · Recruiting
- UM Department Of NeurologyMiami, Florida · Recruiting
- University Of South FloridaTampa, Florida · Recruiting
- Grady Memorial Hospital and ClinicsAtlanta, Georgia · Recruiting
- Parkinsons-Movement Disorder CtrChicago, Illinois · Recruiting
- Rush University Medical CenterChicago, Illinois · Recruiting
- Indiana University HealthIndianapolis, Indiana · Recruiting
- University of Iowa Health CareIowa City, Iowa · Recruiting
- University of Kansas HospitalFairway, Kansas · Recruiting
- Hereditary Neurological Disease CentreWichita, Kansas · Recruiting
- Johns Hopkins UniversityBaltimore, Maryland · Recruiting
- Beth Israel Deaconess Med CtrBoston, Massachusetts · Recruiting
- Henry Ford Health SystemDetroit, Michigan · Recruiting
- Trinity Health MichiganGrand Rapids, Michigan · Recruiting
- Albany Medical CollegeAlbany, New York · Recruiting
- UBMD NeurologyBuffalo, New York · Recruiting
- Columbia University Irving MedicalNew York, New York · Recruiting
- Universi of Rochester School of MedRochester, New York · Recruiting
- University Of NC At Chapel HillChapel Hill, North Carolina · Recruiting
- Duke University Health SystemDurham, North Carolina · Recruiting
- Cleveland Clinic FoundationCleveland, Ohio · Recruiting
- Oregon Health Sciences UniversityPortland, Oregon · Recruiting
- University of PennsylvaniaPhiladelphia, Pennsylvania · Recruiting
- University Of PittsburghPittsburgh, Pennsylvania · Recruiting
- Veracity Neuroscience LLCMemphis, Tennessee · Recruiting
- Vanderbilt University Medical CenterXNashville, Tennessee · Recruiting
- TX Movement Disorder Spec PLLCGeorgetown, Texas · Recruiting
- U of TX Health Science CtHouston, Texas · Recruiting
- The University of Vermont MCBurlington, Vermont · Recruiting
- VCU Health Systems MCVRichmond, Virginia · Recruiting
- University of Washington Medical CenterSeattle, Washington · Recruiting
- Uni Of Wisconsin Hosp And ClinicMadison, Wisconsin · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07326709.
Questions people ask about Novartis's phase 3 votoplam study
Is Novartis's phase 3 votoplam study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-09-22. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for Novartis's phase 3 votoplam study?
The listing names 40 US sites, in Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia and 20 other states. The full list is in the sites section of this page.
Who can join Novartis's phase 3 votoplam study?
About 770 adults with early symptomatic Huntington disease are planned, and 3 of every 5 get votoplam by mouth and the rest a placebo. The main listed requirements are in the pre-check on this page, starting with: ambulatory adults 21 to 70 years old on the day of consent. Only the study team decides who can join.
How do I contact the Novartis's phase 3 votoplam study team?
The listing names this contact: Novartis Pharmaceuticals, 1-888-669-6682, novartis.email@novartis.com. Each site may also list its own contact on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, Novartis. This page restates the public listing in plain words, and nothing here is medical advice; talk with your neurologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07326709, last updated there 2026-09-22. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your neurologist about whether a study is right for you.